115 B-cell repopulation after rituximab in rheumatoid arthritis 12 Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH. 2015; Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 31(20):3356–8. 13 Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, Thomas DC, Flint SM, Kellam P, Jayne DRW, Lyons PA, Smith KGC. 2019; Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 574(7776):122–6. 14 Oksanen J, Blanchet F, Friendly M, et al. 2008. Community Ecology Package: vegan . 15 Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. 2006; Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2):613–20. 16 Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. 2006; Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8):2377–86. 17 Bartelds GM, Wijbrandts C a, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans B a C, Tak PP, Wolbink GJ. 2007; Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 66(7):921–6. 18 van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BAC, Aarden LA. 2006; Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 66(2):253–6. 19 Brezinschek H-P, Rainer F, Brickmann K, Graninger WB. 2012; B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 14(4):R161. 20 Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP. 2016; A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther. 18(1):190. 5
RkJQdWJsaXNoZXIy MTk4NDMw